Failure of normalization of CA19-9 following resection for pancreatic cancer is tantamount to metastatic disease

Annals of Surgical Oncology

Volumn 18, Issue 4, 2011, Pages 1116-1121

  Abdel Misih, Sherif R Z ^a   Hatzaras, Ioannis ^a   Schmidt, Carl ^a   Saab, Tanios Bekaii ^a   Klemanski, Dori ^a   Muscarella, Peter ^a   Melvin, W Scott ^a   Ellison, E Christopher ^a   Bloomston, Mark ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER SURGERY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS RESECTION; PROGNOSIS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CA-19-9 ANTIGEN; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PANCREATECTOMY; PANCREATIC NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79955854559     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-010-1397-1     Document Type: Article

References (19)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-49.
2. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267-77. (Pubitemid 46143304)
3. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) Pancreas Cancer (Version 1.2010). © 2010 National Comprehensive Cancer Network, Inc. Available at: NCCN.org. Accessed 3/25/2010. To view the most recent and complete version of the NCCN GuidelinesTM, go online to NCCN.org.
4. Bloomston M, Frankel WL, Petrocca F, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA. 2007;297: 1901-8. (Pubitemid 46707844)
5. Dilhoff M, Liu J, Frankel W, Croce C, Bloomston M. MicroRNA- 21 is overexpressed in pancreatic cancer and a potential predictor of survival. J Gastrointest Surg. 2008;12(12):2171-6.
6. Bloomston M, Bekaii-Saab TS, Kosuri K, Cowgill SM, Melvin WS, Ellison EC, Muscarella P. Preoperative carbohydrate antigen 19-9 is most predictive of malignancy in older jaundiced patients undergoing pancreatic resection. Pancreas. 2006;33(3):246-9. (Pubitemid 44470139)
7. Muscarella P, Fisher W, Johnson J, Melvin WS. Neoplastic disorders of the pancreas. In: Lott J, editor. Clinical pathology of pancreatic disorders. New Jersey: Humana; 1997. p. 125-63.
8. Hernandez JM, Cowgill SM, Al-Saadi S, et al. CA19-9 velocity predicts disease-free survival and overall survival after pancreatectomy of curative intent. J Gastrointest Surg. 2009;13(2): 349-53.
9. Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JA. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol. 2001;19(15): 3447-55. (Pubitemid 32730080)
10. Rapellino M, Piantino P, Pecchio F, et al. Disappearance curves of tumor markers after radical surgery. Int J Biol Markers. 1994;9(1):33-7. (Pubitemid 24135516)
11. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83. (Pubitemid 17055592)
12. Safi F, Schlosser W, Falkenreck S, Beger HG. Prognostic value of CA19-9 serum course in pancreatic cancer. Hepatogastroenterology. 1998;45(19):253-9. (Pubitemid 28067563)
13. Ong SL, Garcea G, Thomasset SC, et al. Surrogate markers of resectability in patients undergoing exploration of potentially resectable pancreatic adenocarcinoma. J Gastrointest Surg. 2008;12(6):1068-73.
14. Fujioka S, Misawa T, Okamoto T, Gocho T, Futagawa Y, Ishida Y, et al. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma. J Hepatobiliary Pancreat Surg. 2007;14(6):539-44. (Pubitemid 350201463)
15. Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Temero MA. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer. 2005;93(2):195-9. (Pubitemid 41133205)
16. Wong D, Ko AH, Hwang J, Venook AP, Bergsland EK, Tempero MA. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas. 2008;37(3): 269-74.
17. Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez- delCastillo C, Warshaw AL. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol. 2006;24(18):2897-902. (Pubitemid 46630592)
18. Kinsella TJ, Seo Y, Willis J, et al. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer. Am J Clin Oncol. 2008;31(5):446-53.
19. Berger AC, Garcia M Jr, Hoffman J, et al. Postresection CA19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol. 2008;26(36):5918-22.